Valencia – – September 29, 2026 -- Arthex Biotech has appointed Glenn Sblendorio, former CEO of IVERIC bio, as Chairman of its Board of Directors as the clinical-stage RNA therapeutics company advances its lead program ATX-01 through Phase I/IIa trials for myotonic dystrophy type 1 (DM1).